Sign up
CSTL

Castle Biosciences Inc (NASDAQ: CSTL)

Healthcare · Diagnostics & Research

$33.38+0.40 (+1.21%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. CSTL rose 1.21% in the Nov 18 session to $33.38. The borrow fee is 0.28%. Six active firms cover the stock as of Nov 19, 2026; six active firms with targets average $44.33 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuationBroadly in line with peers

P/S 2.8× vs peer median 4.5×

MomentumNeutral

RSI (14) 45.1 (overbought above 70, oversold below 30)

Trend—

—

Short interest7.7% of float

FINRA settlement Oct 30, 2026

CSTL price chart

Price $33.38 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$32.88Nov 18, 2026 session
Previous close
$32.98Nov 17, 2026 close
Day range
$32.34 – $34.09Nov 18, 2026 session
52-week range—
Volume
380.85KNov 18, 2026 session
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

CSTL · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18
Squeeze36Watch—
How the scores work →

How CSTL compares with its industry

Against 44 other US-listed Diagnostics & Research stocks

Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%

Strongest points

  1. Five-year annualized sales growth was 40.6%, higher than 97% of 31 peers.Peer median 7.5% · As of Nov 17, 2026
  2. Trailing-year gross margin was 77.1%, higher than 95% of 41 peers.Peer median 55.0% · As of Nov 17, 2026
  3. Current ratio was 5.28, higher than 85% of 41 peers.Peer median 2.31 · As of Nov 17, 2026

Valuation

Broadly in line with peers

  • Price/sales2.76×4.50×

    Higher than 39% of 44 peers

  • Forward P/E—26.67×

    Not ranked: only 31 of 44 peers report it

  • Price/book2.18×3.74×

    Higher than 28% of 43 peers

Profitability

Profitability metrics are mixed versus peers.

  • Gross margin77.1%55.0%
    Top 10% of peers

    Higher than 95% of 41 peers

  • Operating margin−7.4%0.8%

    Higher than 45% of 40 peers

  • Net margin−6.1%0.0%

    Higher than 37% of 43 peers

  • Return on equity−4.9%0.6%

    Higher than 45% of 40 peers

Growth

Growth metrics are higher than most peers.

  • Quarterly sales growth, year over year23.9%8.1%

    Higher than 80% of 44 peers

  • 5-year sales growth rate40.6%7.5%
    Top 10% of peers

    Higher than 97% of 31 peers

Balance sheet

Balance sheet metrics are higher than most peers.

  • Current ratio5.282.31

    Higher than 85% of 41 peers

  • Debt/equity (total borrowings)0.020.45

    Not ranked: only 26 of 44 peers report it

Momentum

Returns are mixed versus peers.

  • 1-year return−1.7%+11.7%

    Higher than 36% of 42 peers

  • 6-month return+66.7%+35.3%

    Higher than 83% of 42 peers

  • 3-month return+1.4%−0.4%

    Higher than 52% of 42 peers

Compared with 44 other US-listed Diagnostics & Research stocks · fundamentals as of Nov 15, 2026 · prices as of Nov 17, 2026

Upcoming events

— · Upcoming events not available

Analyst consensus

Buy

0Strong Buy
6Buy
0Neutral
0Sell
0Strong Sell

Based on 6 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$40.00
Average$44.33
High$52.00

As of Nov 19, 2026 across 6 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

— · Earnings history not available

Smart-money activity

In the last 60 days: 29 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
Insider sellMAETZOLD DEREK JSell$46.0KForm 4
Insider sellMAETZOLD DEREK JSell$54.1KForm 4
Insider sellMAETZOLD DEREK JSell$128.5KForm 4
Insider sellJuvenal Tobin WSell$112.0KForm 4
Insider sellJuvenal Tobin WSell$99.1KForm 4
Insider sellJuvenal Tobin WSell$107.4KForm 4
Insider sellMAETZOLD DEREK JSell$12.0KForm 4
Insider sellMAETZOLD DEREK JSell$14.1KForm 4
Insider sellMAETZOLD DEREK JSell$37.7KForm 4
Insider sellMAETZOLD DEREK JSell$86.2KForm 4
All smart-money activity →

News and press releases

News and press releases are not available.

All CSTL news →

Company profile

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to

CEO
Mr. Derek J. Maetzold
Headquarters
Friendswood, TX, United States
Employees
1,048
IPO date
Jul 25, 2019
Sector
Healthcare
Industry
Diagnostics & Research

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.